https://www.selleckchem.com/pr....oducts/bms-345541.ht
Non-small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. A membrane-bound form of Hsp70 (mHsp7 which is selectively expressed on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70-targeting NK cells. The randomized phase II clinical trial (EudraCT2008-002130-3 explores tolerability and efficacy of -activated NK cells in patients with NSCLC after radiochemotherapy (R
Like
Comment
Share
